

REPORT TO THE TWENTY-NINTH HAWAII STATE LEGISLATURE 2018

**IN ACCORDANCE WITH THE PROVISIONS OF
SECTION 346-59.9, HAWAII REVISED STATUTES,
ON PSYCHOTROPIC MEDICATION**

**MED-QUEST DIVISION
DEPARTMENT OF HUMAN SERVICES
DECEMBER 2017**

Section 346-59.9, Hawaii Revised Statutes (HRS), Psychotropic Medication, requires the Department of Human Services to report annually on:

- (1) The number of brand-name and generic prescriptions written to which this section applies, and
- (2) The amount expended on brand-name prescriptions and the amount expended on generic prescriptions written each fiscal year to which this section applies.

The information is provided in the tables below. The data is as reported by each QUEST Integrated health plan, Community Care Services and Fee-For-Service program.

Hawaii Medicaid Psychotropic Cost for Fiscal Year 2017

Includes QUEST Integration (QI) Health Plans, Community Care Services (CCS) and Fee-For-Service (FFS).

	Total Number of Claims				Total Expenditure			
	Brand		Generic		Brand		Generic	
	#	%	#	%	\$	%	\$	%
Antipsychotic Total								
7/1/2015-6/30/2016*	8,212	16%	43,549	84%	\$9,867,225	51%	\$9,480,161	49%
7/1/2016-6/30/2017	12,775	18%	58,283	82%	\$19,067,248	69%	\$8,594,922	31%
Antidepressant Total								
7/1/2015-6/30/2016	5,093	4%	132,984	96%	\$1,457,277	33%	\$2,927,020	67%
7/1/2016-6/30/2017	4,438	3%	138,585	97%	\$1,402,041	39%	\$2,196,418	61%
Anti-anxiety Total								
7/1/2015-6/30/2016	427	1%	69,597	99%	\$216,186	28%	\$568,327	72%
7/1/2016-6/30/2017	549	1%	61,748	99%	\$457,303	49%	\$469,889	51%

*Change from last year's reported data is due to health plan's correction of data.

The total cost for psychotropic medication in State Fiscal Year (SFY) 2017 is approximately \$32,200,000. This total includes the QI health plans (\$19,200,000) and the Community Care Services (\$13,000,000) program. The FFS program is minor in total costs (\$21,500).

Hawaii Medicaid Psychotropic Cost: Quest Integration and Fee-For-Service

For comparison, CCS is not included.

		Total Number of Claims				Total Expenditures			
		Brand		Generic		Brand		Generic	
		#	%	#	%	\$	%	\$	%
Antipsychotic									
	7/1/2009-6/30/2010	41,568	77%	12,279	23%	\$20,120,498	93%	\$1,462,845	7%
	7/1/2010-6/30/2011	44,771	76%	13,863	24%	\$25,292,347	95%	\$1,399,257	5%
	7/1/2011-6/30/2012	36,942	60%	24,660	40%	\$23,577,237	81%	\$5,392,685	19%
	7/1/2012-6/30/2013	24,124	38%	38,545	62%	\$18,854,977	78%	\$5,343,676	22%
	7/1/2013-6/30/2014	17,543	38%	29,109	62%	\$15,400,608	81%	\$3,501,443	19%
	7/1/2014-6/30/2015	18,058	36%	32,484	64%	\$15,816,746	76%	\$5,054,661	24%
	7/1/2015-6/30/2016*	5,159	18%	23,837	82%	\$5,828,675	59%	\$4,038,571	41%
	7/1/2016-6/30/2017	6,903	15%	40,1037	85%	\$9,678,890	64%	\$5,506,899	36%
Antidepressant									
	7/1/2009-6/30/2010	22,358	25%	66,509	75%	\$3,403,691	60%	\$2,290,816	40%
	7/1/2010-6/30/2011	18,796	19%	80,114	81%	\$2,900,028	51%	\$2,838,201	49%
	7/1/2011-6/30/2012	13,520	13%	92,124	87%	\$2,487,651	50%	\$2,528,206	50%
	7/1/2012-6/30/2013	9,521	9%	102,226	91%	\$2,274,479	47%	\$2,578,048	53%
	7/1/2013-6/30/2014	5,017	5%	98,423	95%	\$1,428,173	36%	\$2,514,924	64%
	7/1/2014-6/30/2015	5,242	5%	96,203	95%	\$1,349,207	38%	\$2,217,943	62%
	7/1/2015-6/30/2016	4,786	4%	114,760	96%	\$1,375,577	37%	\$2,350,237	63%
	7/1/2016-6/30/2017	3,850	3%	121,910	97%	\$1,209,417	39%	\$1,915,475	61%
Anti-anxiety									
	7/1/2009-6/30/2010	293	1%	52,690	99%	\$40,861	7%	\$585,858	93%
	7/1/2010-6/30/2011	206	<1%	56,699	100%	\$38,126	6%	\$615,984	94%
	7/1/2011-6/30/2012	153	<1%	59,655	100%	\$39,009	6%	\$622,672	94%
	7/1/2012-6/30/2013	114	<1%	54,721	100%	\$44,039	8%	\$503,706	92%
	7/1/2013-6/30/2014	120	<1%	52,292	100%	\$55,603	12%	\$424,190	88%
	7/1/2014-6/30/2015	84	<1%	53,634	100%	\$61,460	14%	\$377,300	86%
	7/1/2015-6/30/2016	415	1%	63,258	99%	\$215,465	30%	\$510,127	70%
	7/1/2016-6/30/2017	517	1%	55,701	99%	\$453,798	51%	\$431,668	49%

*Change from last year's reported data is due to health plan's correction of data.

Medicaid Fee-For-Service (FFS) Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10*	431	77%	121	23%	\$173,656	94%	\$11,761	4%	277	
7/1/10-6/30/11	243	68%	112	32%	\$108,078	91%	\$10,354	9%	201	
7/1/11-6/30/12	160	54%	134	46%	\$71,790	81%	\$16,384	19%	173	
7/1/12-6/30/13	10	24%	32	76%	\$7,623	76%	\$2,371	24%	20	
7/1/13-6/30/14	5	11%	40	89%	\$3,443	42%	\$4,797	58%	14	
7/1/14-6/30/15	4	11%	31	89%	\$3,323	46%	\$3,869	54%	10	
7/1/15-6/30/16	3	5%	62	95%	\$4,106	21%	\$15,938	79%	7	
7/1/16-6/30/17	0	0%	31	100%	\$0	0%	\$2,305	100%	5	
Antidepressant										
7/1/09-6/30/10*	154	22%	561	78%	\$17,861	52%	\$16,566	48%	411	
7/1/10-6/30/11	77	15%	449	85%	\$11,535	40%	\$15,732	60%	324	
7/1/11-6/30/12	39	10%	368	90%	\$6,100	38%	\$9,790	66%	273	
7/1/12-6/30/13	0	0%	102	100%	\$0	0%	\$2,269	100%	49	
7/1/13-6/30/14	0	0%	90	100%	\$0	0%	\$1,766	100%	27	
7/1/14-6/30/15	0	0%	38	100%	\$0	0%	\$783	100%	10	
7/1/15-6/30/16	0	0%	54	100%	\$0	0%	\$1,134	100%	10	
7/1/16-6/30/17	0	0%	100	100%	\$0	0%	\$5,202	100%	16	
Anti-anxiety										
7/1/09-6/30/10*	0	0%	360	100%	\$0	0%	\$2,969	100%	245	
7/1/10-6/30/11	0	0%	263	100%	\$0	0%	\$3,142	100%	202	
7/1/11-6/30/12	0	0%	237	100%	\$0	0%	\$3,092	100%	175	
7/1/12-6/30/13	0	0%	78	100%	\$0	0%	\$687	100%	52	
7/1/13-6/30/14	0	0%	72	100%	\$0	0%	\$578	100%	42	
7/1/14-6/30/15	0	0%	32	100%	\$0	0%	\$302	100%	25	
7/1/15-6/30/16	0	0%	51	100%	\$0	0%	\$319	100%	29	
7/1/16-6/30/17	0	0%	59	100%	\$0	0%	\$410	100%	31	

*FFS Aged, Blind and Disabled moved into QUEST Expanded Access on February 1, 2009.

AlohaCare QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10	5,887	85%	1,022	15%	\$2,182,797	94%	\$141,089	6%	1,259	
7/1/10-6/30/11	6,545	81%	1,460	19%	\$2,915,457	94%	\$183,521	6%	1,410	
7/1/11-6/30/12	5,062	64%	2,887	36%	\$2,614,657	83%	\$523,881	17%	1,392	
7/1/12-6/30/13	3,517	46%	4,138	54%	\$1,951,363	80%	\$484,644	20%	1,220	
7/1/13-6/30/14	2,703	40%	4,010	60%	\$2,323,691	86%	\$365,329	14%	1,088	
7/1/14-6/30/15	1,550	34%	3,021	66%	\$1,404,173	86%	\$224,212	14%	907	
7/1/15-6/30/16	785	16%	4,059	84%	\$794,990	52%	\$743,892	48%	926	
7/1/16-6/30/17	922	16%	4,748	84%	\$1,072,207	61%	\$679,612	39%	966	
Antidepressant										
7/1/09-6/30/10	4,380	26%	12,376	74%	\$602,689	59%	\$423,742	41%	3,355	
7/1/10-6/30/11	3,580	20%	14,613	80%	\$509,803	46%	\$607,128	54%	3,623	
7/1/11-6/30/12	2,303	12%	16,663	88%	\$375,886	38%	\$621,367	62%	3,593	
7/1/12-6/30/13	1,913	10%	17,247	90%	\$274,955	36%	\$489,987	64%	3,314	
7/1/13-6/30/14	712	4%	17,915	96%	\$170,763	24%	\$553,019	76%	3,192	
7/1/14-6/30/15*	259	2%	16,857	98%	\$61,252	17%	\$366,514	83%	3,182	
7/1/15-6/30/16*	291	2%	18,202	98%	\$78,660	20%	\$321,469	80%	3,263	
7/1/16-6/30/17	374	2%	19,255	98%	\$109,221	22%	\$385,603	78%	3,298	
Anti-anxiety										
7/1/09-6/30/10	15	<1%	8,206	100%	\$2,505	3%	\$79,318	97%	1,786	
7/1/10-6/30/11	18	<1%	8,111	100%	\$1,951	2%	\$80,947	98%	1,894	
7/1/11-6/30/12	2	<1%	8,362	100%	\$247	<1%	\$93,660	100%	1,835	
7/1/12-6/30/13	0	0%	6,731	100%	\$0	0%	\$61,849	100%	1,734	
7/1/13-6/30/14	28	<1%	11,583	100%	\$8,176	6%	\$138,556	94%	2,290	
7/1/14-6/30/15	16	<1%	11,658	100%	\$5,809	4%	\$139,536	96%	3,058	
7/1/15-6/30/16	54	<1%	12,269	100%	\$20,744	10%	\$182,755	90%	2,968	
7/1/16-6/30/17	30	<1%	11,588	100%	\$15,365	7%	\$206,044	93%	2,847	

*Change from last year's reported data is due to health plan's correction of data.

HMSA QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10	11,615	83%	2,430	17%	\$4,319,335	96%	\$160,146	4%	2,127*	
7/1/10-6/30/11	11,406	80%	2,810	19%	\$4,847,964	98%	\$103,154	2%	2,171	
7/1/11-6/30/12	9,978	66%	5,290	34%	\$5,009,526	88%	\$664,503	12%	2,221	
7/1/12-6/30/13	7,586	44%	9,642	56%	\$4,626,576	86%	\$768,865	14%	2,469	
7/1/13-6/30/14	7,055	45%	8,755	55%	\$5,011,583	90%	\$555,836	10%	2,429	
7/1/14-6/30/15	6,074	41%	8,770	59%	\$4,866,243	89%	\$598,551	11%	2,214	
7/1/15-6/30/16**	3,458	20%	13,895	80%	\$3,029,597	60%	\$2,003,703	40%	2,439	
7/1/16-6/30/17	3,129	17%	15,743	83%	\$3,313,766	62%	\$1,999,102	38%	2,629	
Antidepressant										
7/1/09-6/30/10	8,864	27%	24,262	73%	\$1,185,654	58%	\$875,185	42%	5,565*	
7/1/10-6/30/11	7,410	19%	30,843	81%	\$1,004,692	51%	\$947,123	49%	6,199	
7/1/11-6/30/12	5,237	13%	35,348	87%	\$904,502	54%	\$781,470	46%	6,442	
7/1/12-6/30/13	3,870	8%	43,422	92%	\$902,444	51%	\$880,628	49%	7,428	
7/1/13-6/30/14	2,376	5%	46,341	95%	\$620,624	42%	\$871,708	58%	7,895	
7/1/14-6/30/15	2,279	4%	50,516	96%	\$562,786	38%	\$909,438	62%	8,276	
7/1/15-6/30/16	2,622	4%	57,011	96%	\$756,377	49%	\$783,261	51%	8,893	
7/1/16-6/30/17	2,812	4%	62,578	96%	\$884,042	50%	\$888,569	50%	9,509	
Anti-anxiety										
7/1/09-6/30/10	18	<1%	11,536	100%	\$5,910	4%	\$137,248	96%	2,360*	
7/1/10-6/30/11	31	<1%	13,316	100%	\$6,803	6%	\$111,448	94%	2,667	
7/1/11-6/30/12	18	<1%	13,545	100%	\$4,540	4%	\$116,889	96%	2,488	
7/1/12-6/30/13	34	<1%	17,584	100%	\$10,378	8%	\$118,503	92%	3,606	
7/1/13-6/30/14	44	<1%	21,076	100%	\$18,801	14%	\$115,739	86%	4,461	
7/1/14-6/30/15	30	<1%	22,374	100%	\$37,788	29%	\$92,723	71%	4,979	
7/1/15-6/30/16	24	<1%	24,761	100%	\$60,906	43%	\$81,824	57%	5,374	
7/1/16-6/30/17	50	<1%	22,777	100%	\$73,147	46%	\$86,197	54%	5,205	

*The change of a pharmacy claims processor during this period results in some inconsistencies in data sets.

**Change from last year's reported data is due to health plan's correction of data.

Kaiser QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10	714	53%	628	47%	\$210,251	98%	\$3,932	2%	289	
7/1/10-6/30/11	853	54%	730	46%	\$301,307	98%	\$6,176	2%	360	
7/1/11-6/30/12	625	38%	1,023	62%	\$258,603	89%	\$32,444	11%	372	
7/1/12-6/30/13	404	24%	1,307	76%	\$204,739	92%	\$17,232	8%	335	
7/1/13-6/30/14	391	24%	1,251	76%	\$242,048	94%	\$16,517	6%	321	
7/1/14-6/30/15	252	22%	905	78%	\$197,867	75%	\$65,471	25%	353	
7/1/15-6/30/16	49	3%	1,379	97%	\$48,694	27%	\$134,555	73%	417	
7/1/16-6/30/17	109	5%	1,972	95%	\$102,231	66%	\$52,436	34%	416	
Antidepressant										
7/1/09-6/30/10	497	8%	5,857	92%	\$75,263	66%	\$38,422	34%	1,181	
7/1/10-6/30/11	463	6%	6,968	94%	\$80,249	66%	\$41,292	34%	1,378	
7/1/11-6/30/12	485	5%	8,444	95%	\$107,488	66%	\$55,350	34%	1,589	
7/1/12-6/30/13	458	5%	7,943	95%	\$124,731	71%	\$51,058	29%	1,398	
7/1/13-6/30/14	248	4%	6,811	96%	\$82,406	52%	\$77,015	49%	1,358	
7/1/14-6/30/15	20	<1%	5,582	100%	\$8,669	14%	\$51,510	86%	1,524	
7/1/15-6/30/16	37	<1%	6,143	100%	\$17,195	30%	\$39,477	70%	1,721	
7/1/16-6/30/17	85	1%	9,044	99%	\$28,566	35%	\$53,950	65%	1,695	
Anti-anxiety										
7/1/09-6/30/10	1	<1%	2,469	100%	\$147	3%	\$4,851	97%	648	
7/1/10-6/30/11	1	<1%	2,789	100%	\$661	11%	\$5,101	89%	777	
7/1/11-6/30/12	15	<1%	2,972	100%	\$5,503	53%	\$4,915	47%	867	
7/1/12-6/30/13	13	<1%	2,646	100%	\$4,555	53%	\$4,095	47%	758	
7/1/13-6/30/14	13	<1%	2,374	100%	\$6,912	65%	\$3,746	35%	760	
7/1/14-6/30/15	2	<1%	2,758	100%	\$50	1%	\$3,843	99%	898	
7/1/15-6/30/16	1	<1%	3,403	100%	\$48	<1%	\$11,032	100%	1,041	
7/1/16-6/30/17	3	<1%	3,539	100%	\$69	<1%	\$17,336	100%	986	

Ohana Health Quest Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers
	Brand		Generic		Brand		Generic		
	#	%	#	%	\$	%	\$	%	
Antipsychotic									
7/1/09-6/30/10	15,653	76%	5,068	24%	\$7,510,115	92%	\$645,522	8%	1,944
7/1/10-6/30/11	18,771	76%	6,008	24%	\$10,069,923	93%	\$701,013	7%	2,164
7/1/11-6/30/12	15,357	58%	11,280	42%	\$9,537,668	75%	\$3,122,545	25%	2,129
7/1/12-6/30/13	9,555	35%	17,735	65%	\$7,532,671	66%	\$3,936,457	34%	2,216
7/1/13-6/30/14*	1,123	8%	12,628	92%	\$1,274,736	28%	\$3,234,847	72%	1,691
7/1/14-6/30/15*	3,837	27%	10,398	73%	\$3,747,958	62%	\$2,273,132	38%	1,757
7/1/15-6/30/16*	5,975	31%	13,067	69%	\$5,172,198	67%	\$2,515,781	32%	2,321
7/1/16-6/30/17	1,795	12%	12,834	88%	\$2,682,837	60%	\$1,807,174	40%	1,744
Antidepressant									
7/1/09-6/30/10	5,462	26%	15,688	74%	\$786,111	60%	\$519,290	40%	2,559
7/1/10-6/30/11	5,335	22%	19,287	78%	\$754,409	49%	\$800,750	51%	2,846
7/1/11-6/30/12	4,310	16%	22,277	84%	\$736,653	49%	\$774,715	51%	2,856
7/1/12-6/30/13	2,561	9%	24,647	91%	\$631,605	42%	\$881,158	58%	2,904
7/1/13-6/30/14*	239	1%	22,163	99%	\$67,074	9%	\$679,477	91%	3,241
7/1/14-6/30/15*	548	2%	22,174	98%	\$128,668	12%	\$983,688	88%	3,403
7/1/15-6/30/16*	1,717	7%	24,234	93%	\$451,713	31%	\$984,953	69%	3,624
7/1/16-6/30/17	500	2%	21,403	98%	\$142,570	29%	\$351,042	71%	3,119
Anti-anxiety									
7/1/09-6/30/10	76	<1%	18,057	100%	\$21,672	11%	\$171,815	89%	2,931
7/1/10-6/30/11	49	<1%	19,805	100%	\$17,288	8%	\$191,471	92%	3,032
7/1/11-6/30/12	48	<1%	21,810	100%	\$18,985	8%	\$207,492	92%	3,128
7/1/12-6/30/13	51	<1%	18,104	100%	\$22,898	12%	\$173,596	88%	2,838
7/1/13-6/30/14*	208	2%	12,765	98%	\$120,112	52%	\$108,888	48%	2,482
7/1/14-6/30/15*	419	3%	13,056	97%	\$153,167	51%	\$148,628	49%	2,529
7/1/15-6/30/16*	335	2%	15,821	98%	\$133,689	42%	\$183,472	58%	2,704
7/1/16-6/30/17	434	4%	11,477	96%	\$365,217	85%	\$62,813	15%	2,359

*Change from last year's reported data is due to health plan's correction of data.

United HealthCare QUEST Integration Psychotropic Cost

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers	
	Brand		Generic		Brand		Generic			
	#	%	#	%	\$	%	\$	%		
Antipsychotic										
7/1/09-6/30/10	7,268	71%	3,010	29%	\$5,724,344	92%	\$500,395	8%	2,045	
7/1/10-6/30/11	6,953	72%	2,743	28%	\$7,049,618	95%	\$395,039	5%	1,634	
7/1/11-6/30/12	5,760	58%	4,046	42%	\$6,084,993	85%	\$1,032,928	15%	1,493	
7/1/12-6/30/13	3,052	35%	5,691	65%	\$4,532,005	83%	\$902,203	17%	1,593	
7/1/13-6/30/14	2,132	34%	4,212	66%	\$3,219,152	92%	\$290,152	8%	1,500	
7/1/14-6/30/15*	1,663	30%	3,798	70%	\$2,809,915	89%	\$358,261	11%	1,183	
7/1/15-6/30/16*	919	17%	4,630	83%	\$2,020,292	62%	\$1,230,324	38%	1,211	
7/1/16-6/30/17	948	17%	4,809	83%	\$2,507,849	72%	\$966,270	28%	1,313	
Antidepressant										
7/1/09-6/30/10	3,001	28%	7,765	72%	\$736,113	64%	\$417,611	36%	2,697	
7/1/10-6/30/11	1,931	20%	7,954	80%	\$539,340	56%	\$426,176	44%	2,093	
7/1/11-6/30/12	1,146	11%	9,024	89%	\$357,022	56%	\$285,514	44%	1,979	
7/1/12-6/30/13	719	8%	8,865	92%	\$340,744	56%	\$272,948	44%	2,301	
7/1/13-6/30/14	425	5%	8,550	95%	\$217,360	46%	\$258,976	54%	2,519	
7/1/14-6/30/15	147	2%	9,031	98%	\$81,075	21%	\$297,782	79%	2,532	
7/1/15-6/30/16*	120	1%	9,392	99%	\$710,044	24%	\$223,818	76%	2,598	
7/1/16-6/30/17	79	1%	9,530	99%	\$45,018	16%	\$231,109	84%	2,663	
Anti-anxiety										
7/1/09-6/30/10	183	<1%	2,062	99%	\$10,627	5%	\$189,657	95%	2,640	
7/1/10-6/30/11	107	<1%	12,415	99%	\$11,423	5%	\$223,875	95%	2,880	
7/1/11-6/30/12	70	<1%	12,729	99%	\$9,734	5%	\$196,624	95%	2,813	
7/1/12-6/30/13	16	<1%	9,578	100%	\$6,208	4%	\$144,976	96%	2,779	
7/1/13-6/30/14	8	<1%	6,748	100%	\$4,166	6%	\$61,766	94%	1,917	
7/1/14-6/30/15	1	<1%	7,123	100%	\$724	1%	\$49,736	99%	1,949	
7/1/15-6/30/16*	1	<1%	7,020	100%	\$78	<1%	\$53,372	100%	2,028	
7/1/16-6/30/17	0	0%	6,261	100%	\$0	0%	\$58,868	100%	1,906	

*Change from last year's reported data is due to health plan's correction of data.

Community Care Services (CCS)

	Total Number of Claims				Total Expenditure				Total No. Unique Utilizers
	Brand		Generic		Brand		Generic		
	#	%	#	%	\$	%	\$	%	
Antipsychotic									
7/1/14-6/30/15	8,485	33%	17,085	67%	\$9,467,667	71%	\$3,950,018	29%	2,365
7/1/15-6/30/16	3,053	13%	19,712	87%	\$4,038,550	43%	\$5,441,590	57%	2,286
7/1/16-6/30/17	5,872	24%	18,146	76%	\$9,388,358	75%	\$3,088,022	25%	2,149
Antidepressant									
7/1/14-6/30/15	622	3%	19,924	97%	\$159,353	15%	\$916,810	85%	2,167
7/1/15-6/30/16	307	2%	18,224	98%	\$81,700	12%	\$576,783	88%	2,012
7/1/16-6/30/17	588	3%	16,675	97%	\$192,624	41%	\$280,943	59%	1,785
Anti-anxiety									
7/1/14-6/30/15	16	<1%	6,734	100%	\$1,347	2%	\$81,480	98%	1,044
7/1/15-6/30/16	12	<1%	6,339	100%	\$721	1%	\$58,200	99%	981
7/1/16-6/30/17	32	<1%	6,047	100%	\$3,505	8%	\$38,221	92%	899

*Change from last year's reported data is due to health plan's correction of data.

Discussion

This State Fiscal Year (SFY) 2016-2017 report utilizes the term “QUEST Integration” to reflect the Medicaid health plans for SFY 2017. The data is as reported by each QUEST Integrated health plan, Community Care Services and Fee-For-Service program.

Previously Act 205, SLH 2010¹, effective on July 1, 2011, was implemented by the health plans during different quarters in State Fiscal Year (SFY) 2010-2011². SFY 2011-2012, SFY 2012-2013 and SFY 2013–2014 each are a full year of all the plans complying with Act 205 without changes in the law or the program. Trends are noted. Data for SFY 2009-2010, prior to the implementation of Act 205, SLH 2010, is represented for comparison purposes.

Four of the five Medicaid managed care plans had data updates. The following are noted:

- 97% of the antidepressant prescriptions are filled as a generic and account for 61% of the antidepressant expenditures. Although utilization has increased by 4%, total antidepressant costs are down 18%. Two generic antidepressant medications were available at the end of 2016 and beginning of 2017.
- 99% of the anti-anxiety prescriptions are filled as a generic and account for 51% of the anti-anxiety expenditures. Updated data trends a decrease in generic prescriptions by 11% and expenditures for anti-anxiety medications increased by 18%. This is minor when compared to the cost of the anti-depressant and anti-psychotropic prescriptions.
- 82% of the anti-psychotropic prescriptions are filled as a generic and account for 31% of the anti-psychotropic expenditures. Although the total utilization is 37% higher than last fiscal year, the total costs increased by 43%. One generic anti-psychotic was available at the end of 2016.

¹ Access to brand medication is available after two generic failures are documented for antidepressant and anti-anxiety medications.

² Different approaches and combinations were initiated by the different plans during SFY 2010-2011, such as the following: Preferred Drug Lists/Formulary Coverage; Prospective DUR edits; Point-Of-Sale messaging; Step Therapy; Prior Authorization; Provider Education; and Call Center intervention.